phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.37489/2588-0527-2021-1-4-8phgenomics-217Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWАктуальность использования фармакогенетического подхода для прогнозирования индивидуальных особенностей фармакокинетики и профиля безопасности апиксабанаImportance of using a pharmacogenetic approach to predict individual pharmacokinetics and safety profile of apixabanhttps://orcid.org/0000-0002-6417-9535ФединаЛ. В.FedinaL. V.

Федина Людмила Владимировна, аспирант кафедры клинической фармакологии и терапии им. Б.Е. Вотчала; врач клинический фармаколог Врач-клинический фармаколог

Москва

Fedina Lyudmila V., postgraduate student of the Department of Clinical Pharmacology and Therapy named after Academician B.E. Votchal; Clinical Pharmacologist

Moscow

https://orcid.org/0000-0002-2970-3442СычёвИ. Н.SychevI. N.

Сычёв Игорь Николаевич, к. м. н., доцент кафедры клинической фармакологии и терапии; Заведующий отделением клинической фармакологии

Москва

Sychev Igor N., Cand. Sci. (Med.), Associate Professor of the Department of Clinical Pharmacology and Therapy; Head of the Department of Clinical Pharmacology

Moscow

https://orcid.org/0000-0002-4496-3680Сычёвд А.SychevD. A.

Сычёв Дмитрий Алексеевич, д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии им. Б.Е. Вотчала

SPIN-код: 4525-7556

Москва

Sychev Dmitry A., Dr. Sci. (Med.), Professor, Corresponding Member RAS, Rector, Head Department of the Clinical Pharmacology and Therapy named after Academician B.E. Votchal

SPIN code: 4525-7556

Moscow

dimasychev@mail.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФ; Государственное бюджетное учреждение здравоохранения города Москвы «Городская клиническая больница имени С.С. Юдина Департамента здравоохранения города Москвы»РоссияRussian Medical Academy of Continuing Professional Education; S.S. Yudin State Clinical Hospital of the Moscow Department of Health Care»Russian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» МЗ РФРоссияRussian Medical Academy of Continuing Professional EducationRussian Federation2021070120220148Copyright © Федина Л.В., Сычёв И.Н., Сычёв д.А., 20222022Федина Л.В., Сычёв И.Н., Сычёв д.А.Fedina L.V., Sychev I.N., Sychev D.A.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/217

В последние годы наблюдается тенденция к увеличению назначения пероральных антикоагулянтов прямого действия (ПОАК) из-за благоприятной фармакокинетики и фармакодинамики без необходимости регулярного мониторинга коагуляции. Однако недавние исследования документально подтвердили индивидуальную вариабельность уровней DOAC в плазме. Фармакогенетика ПОАК — относительно новая область исследований. Необходимо понять роль фармакогенетики в адаптации антикоагулянтной терапии в соответствии с генетическими особенностями пациента. Этот научный обзор актуальных данных о влиянии различных полиморфизмов генов на фармакокинетику апиксабана расширяет понимание клинической значимости генотипирования для эфективности и безопасности лечения.

In recent years, there has been a trend towards increased prescribing of direct-acting oral anticoagulants (DOACs) due to favourable pharmacokinetics and pharmacodynamics without the need for regular coagulation monitoring. However, recent studies have documented individual variability in plasma DOAC levels. DOAC pharmacogenetics is a relatively new area of research. There is a need to understand the role of pharmacogenetics in the adaptation of anticoagulant therapy according to a patient’s genetic characteristics. This scientific review of current data on the impact of different gene polymorphisms on apixaban pharmacokinetics broadens the understanding of the clinical relevance of genotyping for treatment efficacy and safety.

апиксабанПОАКфармакогенетикаперсонализированная медицинаABCB1CYP3A4CYP3A5apixabanDOACpharmacogeneticspersonalized medicineABCB1CYP3A4CYP3A5ReferencesRoth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010.Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010.Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611–1617. DOI: 10.1111/ j.1538-7836.2005.01415.x.Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611–1617. DOI: 10.1111/ j.1538-7836.2005.01415.x.Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 populationbased studies: a systematic review. The Lancet Neurology. 2009;8(4):355–369. DOI: 10.1016/S1474-4422(09)70025-0.Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 populationbased studies: a systematic review. The Lancet Neurology. 2009;8(4):355–369. DOI: 10.1016/S1474-4422(09)70025-0.Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: A 15-year retrospective cohort study of routine clinical practice. The Bone & Joint Journal. 2014;96-B(4):479–485. DOI: 10.1302/0301-620X.96B4.33209.Pedersen AB, Mehnert F, Sorensen HT, Emmeluth C, Overgaard S, Johnsen SP. The risk of venous thromboembolism, myocardial infarction, stroke, major bleeding and death in patients undergoing total hip and knee replacement: A 15-year retrospective cohort study of routine clinical practice. The Bone & Joint Journal. 2014;96-B(4):479–485. DOI: 10.1302/0301-620X.96B4.33209.Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in Orthopedic Surgery Patients. Chest. 2012;141(2):e278S–e325S. DOI: 10.1378/chest.11-2404.Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in Orthopedic Surgery Patients. Chest. 2012;141(2):e278S–e325S. DOI: 10.1378/chest.11-2404.Vazquez S, Rondina MT. Direct oral anticoagulants (DOACs). Vascular Medicine. 2015;20(6):575–577. DOI: 10.1177/1358863X15600256.Vazquez S, Rondina MT. Direct oral anticoagulants (DOACs). Vascular Medicine. 2015;20(6):575–577. DOI: 10.1177/1358863X15600256.Holford NHG. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. Understanding the dose-effect relationship. Clin. Pharmacokinet. 1986;11(6):483–504. DOI: 10.2165/00003088-198611060-00005.Holford NHG. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. Understanding the dose-effect relationship. Clin. Pharmacokinet. 1986;11(6):483–504. DOI: 10.2165/00003088-198611060-00005.Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy. 2018;38(6):588–596. DOI: 10.1002/phar.2089.Shendre A, Parmar GM, Dillon C, Beasley TM, Limdi NA. Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. Pharmacotherapy. 2018;38(6):588–596. DOI: 10.1002/phar.2089.Barnes G. Predicting the Quality of Warfarin Therapy: Reframing the Question. Thromb Haemost. 2019;119(04):509–511. DOI: 10.1055/s-0039-1681060.Barnes G. Predicting the Quality of Warfarin Therapy: Reframing the Question. Thromb Haemost. 2019;119(04):509–511. DOI: 10.1055/s-0039-1681060.Wu AH. Pharmacogenomic-guided dosing for warfarin: too little too late? Personalized Medicine. 2018;15(2):71–73. DOI: 10.2217/pme-2017-0080.Wu AH. Pharmacogenomic-guided dosing for warfarin: too little too late? Personalized Medicine. 2018;15(2):71–73. DOI: 10.2217/pme-2017-0080.Shnayder NA, Petrova MM, Shesternya PA, et al. Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines. 2021;9(5):451. DOI: 10.3390/biomedicines9050451.Shnayder NA, Petrova MM, Shesternya PA, et al. Using Pharmacogenetics of Direct Oral Anticoagulants to Predict Changes in Their Pharmacokinetics and the Risk of Adverse Drug Reactions. Biomedicines. 2021;9(5):451. DOI: 10.3390/biomedicines9050451.Skripka AI, Kogay VV, Listratov AI, Sokolova AA, Napalkov DA, Fomin VV. Personalized approach for direct oral anticoagulant prescription: from theory to practice. Terapevticheskii arkhiv. 2019;91(7):111–120. DOI: 10.26442/00403660.2019.07.000045.Skripka AI, Kogay VV, Listratov AI, Sokolova AA, Napalkov DA, Fomin VV. Personalized approach for direct oral anticoagulant prescription: from theory to practice. Terapevticheskii arkhiv. 2019;91(7):111–120. DOI: 10.26442/00403660.2019.07.000045.Brighton T. Experimental and clinical pharmacology: New oral anticoagulant drugs - mechanisms of action. Aust Prescr. 2010;33(2):38–41. DOI: 10.18773/austprescr.2010.017.Brighton T. Experimental and clinical pharmacology: New oral anticoagulant drugs - mechanisms of action. Aust Prescr. 2010;33(2):38–41. DOI: 10.18773/austprescr.2010.017.Becker R, Alexander J, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010;104(11):976–983. DOI: 10.1160/TH10-04-0247.Becker R, Alexander J, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010;104(11):976–983. DOI: 10.1160/TH10-04-0247.Savinova AV, Petrova MM, Shnayder NA, Bochanova EN, Nasyrova RF. Pharmacokinetics and Pharmacogenetics of Apixaban. Racionalʹnaâ farmakoterapiâ v kardiologii. 2020;16(5):852–860. DOI: 10.20996/1819-6446-2020-10-17.Savinova AV, Petrova MM, Shnayder NA, Bochanova EN, Nasyrova RF. Pharmacokinetics and Pharmacogenetics of Apixaban. Racionalʹnaâ farmakoterapiâ v kardiologii. 2020;16(5):852–860. DOI: 10.20996/1819-6446-2020-10-17.Byon W, Nepal S, Schuster AE, Shenker A, Frost CE. Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects. The Journal of Clinical Pharmacology. 2018;58(7):965–971. DOI: 10.1002/jcph.1097.Byon W, Nepal S, Schuster AE, Shenker A, Frost CE. Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects. The Journal of Clinical Pharmacology. 2018;58(7):965–971. DOI: 10.1002/jcph.1097.Raghavan N, Frost CE, Yu Z, et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metab Dispos. 2009;37(1):74–81. DOI: 10.1124/dmd.108.023143.Raghavan N, Frost CE, Yu Z, et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metab Dispos. 2009;37(1):74–81. DOI: 10.1124/dmd.108.023143.He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129–139. DOI: 10.1007/s13318-011-0037-x.He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129–139. DOI: 10.1007/s13318-011-0037-x.Wang X, Mondal S, Wang J, et al. Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects. Am J Cardiovasc Drugs. 2014;14(2):147–154. DOI: 10.1007/s40256-013-0055-y.Wang X, Mondal S, Wang J, et al. Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects. Am J Cardiovasc Drugs. 2014;14(2):147–154. DOI: 10.1007/s40256-013-0055-y.Wang L, Raghavan N, He K, et al. Sulfation of O -Demethyl Apixaban: Enzyme Identification and Species Comparison. Drug Metab Dispos. 2009;37(4):802–808. DOI: 10.1124/dmd.108.025593.Wang L, Raghavan N, He K, et al. Sulfation of O -Demethyl Apixaban: Enzyme Identification and Species Comparison. Drug Metab Dispos. 2009;37(4):802–808. DOI: 10.1124/dmd.108.025593.Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–1279. DOI: 10.1007/s40262-019-00775-z.Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin Pharmacokinet. 2019;58(10):1265–1279. DOI: 10.1007/s40262-019-00775-z.Ašić A, Marjanović D, Mirat J, Primorac D. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. Personalized Medicine. 2018;15(3):209–221. doi: 10.2217/pme-2017-0092.Ašić A, Marjanović D, Mirat J, Primorac D. Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives. Personalized Medicine. 2018;15(3):209–221. doi: 10.2217/pme-2017-0092.Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. JPM. 2021;11(1):37. DOI: 10.3390/jpm11010037.Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. JPM. 2021;11(1):37. DOI: 10.3390/jpm11010037.Ueshima S, Hira D, Fujii R, et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenetics and Genomics. 2017;27(9):329–336. DOI: с10.1097/FPC.0000000000000294.Ueshima S, Hira D, Fujii R, et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenetics and Genomics. 2017;27(9):329–336. DOI: с10.1097/FPC.0000000000000294.SNPedia CYP3A5. [Internet]; [cited 2021 Oct 27] Available from: https://www.snpedia.com/index.php/CYP3A5.SNPedia CYP3A5. [Internet]; [cited 2021 Oct 27] Available from: https://www.snpedia.com/index.php/CYP3A5.Kang R-H, Jung S-M, Kim K-A, et al. Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients. Journal of Clinical Psychopharmacology. 2009;29(3):272–277. DOI: 10.1097/JCP.0b013e3181a289e0.Kang R-H, Jung S-M, Kim K-A, et al. Effects of CYP2D6 and CYP3A5 Genotypes on the Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Korean Schizophrenic Patients. Journal of Clinical Psychopharmacology. 2009;29(3):272–277. DOI: 10.1097/JCP.0b013e3181a289e0.Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. PGPM. 2018; Volume 11:43–49. DOI: 10.2147/PGPM.S157111.Kryukov AV, Sychev DA, Andreev DA, et al. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. PGPM. 2018; Volume 11:43–49. DOI: 10.2147/PGPM.S157111.Dimatteo C, D’Andrea G, Vecchione G, et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thrombosis Research. 2016;145:24–26. doi: 10.1016/j.thromres.2016.07.005.Dimatteo C, D’Andrea G, Vecchione G, et al. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability. Thrombosis Research. 2016;145:24–26. doi: 10.1016/j.thromres.2016.07.005.CYP1A2 – SNPedia. [Internet]; [cited 2021 Oct 27] Available from: https://www.snpedia.com/index.php/CYP1A2.CYP1A2 – SNPedia. [Internet]; [cited 2021 Oct 27] Available from: https://www.snpedia.com/index.php/CYP1A2.Kanuri SH, Kreutz RP. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. JPM. 2019;9(1):7. DOI: 10.3390/jpm9010007.Kanuri SH, Kreutz RP. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants. JPM. 2019;9(1):7. DOI: 10.3390/jpm9010007.Carlini EJ, Raftogianis RB, Wood TC, et al. Sulfation pharmacogenetics:SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects: Pharmacogenetics. 2001;11(1):57–68. DOI: 10.1097/00008571-200102000-00007.Carlini EJ, Raftogianis RB, Wood TC, et al. Sulfation pharmacogenetics:SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects: Pharmacogenetics. 2001;11(1):57–68. DOI: 10.1097/00008571-200102000-00007.Nagar S, Walther S, Blanchard RL. Sulfotransferase (SULT) 1A1 Polymorphic Variants * 1, * 2, and * 3 Are Associated with Altered Enzymatic Activity, Cellular Phenotype, and Protein Degradation. Mol Pharmacol. 2006;69(6):2084–2092. DOI: 10.1124/mol.105.019240.Nagar S, Walther S, Blanchard RL. Sulfotransferase (SULT) 1A1 Polymorphic Variants * 1, * 2, and * 3 Are Associated with Altered Enzymatic Activity, Cellular Phenotype, and Protein Degradation. Mol Pharmacol. 2006;69(6):2084–2092. DOI: 10.1124/mol.105.019240.Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol Sulfotransferase Pharmacogenetics in Humans: Association of CommonSULT1A1Alleles with TS PST Phenotype. Biochemical and Biophysical Research Communications. 1997;239(1):298–304. DOI: 10.1006/bbrc.1997.7466.Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol Sulfotransferase Pharmacogenetics in Humans: Association of CommonSULT1A1Alleles with TS PST Phenotype. Biochemical and Biophysical Research Communications. 1997;239(1):298–304. DOI: 10.1006/bbrc.1997.7466.

The authors declare that there are no conflicts of interest present.